CORT — Corcept Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapFalling Star

Annual income statement for Corcept Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	366	402	482	675	761
Cost of Revenue
Gross Profit	361	396	476	664	748
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	242	289	375	538	717
Operating Profit	124	113	107	137	44.8
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	125	116	125	161	66.5
Provision for Income Taxes
Net Income After Taxes	113	101	106	141	99.7
Net Income Before Extraordinary Items
Net Income	113	101	106	141	99.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	113	101	106	141	99.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.893	0.875	0.95	1.24	0.831